For their work on this study: Fr.Ma. was supported by the Edmond J. Safra Fellowship in Movement Disorders, the Edmond J. Safra Movement Disorders Research Career Development Award (Grant ID: MJFF-023893), the American Parkinson Disease Association and the David Pearlman Charitable Foundation; Cr.Te. received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06; Ai.Sa. was supported by La Caixa Postgraduate Abroad fellowship; Ba.Vo. was funded by the German Research Foundation DFG VO 2138/7–1 grant 469177153; No.Es. was supported by a Ramón y Cajal Fellowship RYC2021–034267-I and a research grant PID2022–137011OA-I00 funded by the Spanish Ministry of Science and the European Union; Pa.A.Le. was supported by a Royal Society Industry Fellowship (IF\R2\222002) with LifeArc technologies; St.Ef. was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1'; Re.Bu. was supported by the German Academic Exchange Service (DAAD) as part of the German-Arab Transformation Program Line 4 (Project-ID 57166498); Gu.Co. was supported by the Global Parkinson's Genetics Program (GP2), which is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (
https://gp2.org; Grant ID: MJFF-024876); Ay.N.Ba. and Tu.Gü. were supported by Suna and İnan Kıraç Foundation and Koç University School of Medicine, Istanbul, Turkey. Mi.Ze. received research support from the German Research Foundation (DFG 458949627; ZE 1213/2–1). Mi.Ze. acknowledges grant support by the European Joint Programme on Rare Diseases (EJP RD Joint Transnational Call 2022), and the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as by the Technical University of Munich – Institute for Advanced Study. Mi.Ze.’s research is also supported by a “Schlüsselprojekt” grant from the Else Kröner-Fresenius-Stiftung (2022_EKSE.185). Vi.Bo. received financial support from the Stichting Parkinson Fonds, The Netherlands, Grant. n. 1880. Part of this study (Br.Ch., An.Kw., Ma.Ch., Ea.Ng., Sz.Fa.) was supported by the Society for the Relief of Disabled Children (SRDC) and the Commissioned Paediatric Research at Hong Kong Children Hospital (PR-HKU-4) under the Health and Medical Research Fund (HMRF) by the Hong Kong Food and Health Bureau. This research was supported in part by the Intramural research Program of the NIH, National institute on Aging. Part of this work was supported by grants from the Cure Alzheimer's Fund and The Pershing Square Foundation to He.St. Su.Le. received grants from Fondation pour la Recherche Médicale (FRM, MND202004011718), la Fondation de France, France-Parkinson Association, la Fédération pour la Recherche sur le Cerveau (FRC) and the French program “Investissements d’avenir” (ANR-10-IAIHU-06). Cr.Te., Th.Co., Cl.Pi, Ma.Ca, Ba.A.Ha., Gu.Co., Su.Le. and Al.Br. were supported by the RMF through the project “DBS - From genetic mutations to motor circuit dysfunctions & recovery”. He.Ho. was funded by the MRC (MR/S01165X/1, MR/S005021/1, G0601943, MR/V012177/1), The National Institute for Health Research, University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Brain Research UK, Sparks GOSH Charity, the Rosetrees Trust PhD Plus award (PhD2022\100042) and Global Parkinson's Genetic Program (GP2; Grant ID: MJFF-022153).